Advanced search
Publication Cover
Pragmatic and Observational Research Volume 14, 2023 - Issue
Submit an article Journal homepage
316
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia

Giacomo M Bruno1 Department of Drug Sciences, Center of Pharmaceuticals Economics and Medical Technologies Evaluation, CEFAT.Unipv - University of Pavia at Centro di Ricerca SAVE Studi, Milano, Italy;2 S.A.V.E. Research Center - Studi Analisi Valutazioni Economiche, Milano, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4571-654X
ORCID Icon,
Maria Chiara Valentino2 S.A.V.E. Research Center - Studi Analisi Valutazioni Economiche, Milano, ItalyORCID Iconhttps://orcid.org/0000-0002-8736-3503
ORCID Icon,
Alessandra Brunetti3 Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-6345-6991
ORCID Icon,
Sergio Di Matteo2 S.A.V.E. Research Center - Studi Analisi Valutazioni Economiche, Milano, Italy
,
Ivan Begovic2 S.A.V.E. Research Center - Studi Analisi Valutazioni Economiche, Milano, Italy
,
Edoardo Croce4 Scientific Direction - IRCCS istituto Ortopedico Galeazzi, Milan, Italy
,
Garifallia Sakellariou5 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
,
Serena Bugatti6 Department of Internal Medicine and Therapeutics, Division of Rheumatology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Pietro Perotti7 U.O.C. Epidemiological Observatory – Health Protection Agency of Pavia (ATS Pavia), Pavia, Italy
,
Silvia Vecchio7 U.O.C. Epidemiological Observatory – Health Protection Agency of Pavia (ATS Pavia), Pavia, Italy
,
Simona Migliazza7 U.O.C. Epidemiological Observatory – Health Protection Agency of Pavia (ATS Pavia), Pavia, Italy
,
Roberto Langella8 SIFO Regional Secretariat - Società Italiana di Farmacia Ospedaliera e dei Servizi Farmaceutici delle Aziende Sanitarie, Milano, ItalyORCID Iconhttps://orcid.org/0000-0002-6096-3007
ORCID Icon &
Giorgio L Colombo1 Department of Drug Sciences, Center of Pharmaceuticals Economics and Medical Technologies Evaluation, CEFAT.Unipv - University of Pavia at Centro di Ricerca SAVE Studi, Milano, Italy;2 S.A.V.E. Research Center - Studi Analisi Valutazioni Economiche, Milano, ItalyORCID Iconhttps://orcid.org/0000-0002-5790-8891
ORCID Icon show all
Pages 29-38 | Received 26 Nov 2022, Accepted 03 Apr 2023, Published online: 19 Apr 2023

References

  • Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867–868. doi:10.1001/jama.2018.10136
  • Casula M, Tragni E, Catapano AL. I database amministrativi come fonti di dati per la ricerca farmaco epidemiologica [Administrative databases as data sources for drug-epidemiological research]. CARE. 2011;1:33–36. Italian.
  • Colombo GC, Pastorelli L. Dall’impiego dei Database amministrativi in Sanità ai Bigdata: definizione, utilizzo, opportunità e criticità. [From administrative databases in Healthcare to Big Data: definition, use, opportunities and critical issues]. ClinicoEconomics Italian Article Outcomes Res. 2015;2015:37–48 Italian.
  • AIFA. Agenzia Italiana del Farmaco – Position Paper sui Farmaci Biosimilari - Versione definitiva 13.05.2013. Available from: https://www.aifa.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf. Accessed May 13, 2013.
  • Barnes T, Wong E, Thakrar K, et al. The resource cost of switching stable rheumatology patients from an originator biologic to a biosimilar in the UK. Value Health. 2017;20(9):A543. doi:10.1016/j.jval.2017.08.821
  • Rezk MF, Pieper B. Effetto nocebo e aderenza terapeutica treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017;4:209–218. doi:10.1007/s40744-017-0085-z
  • Leonard E, Wascovich M, Oskouei S, et al. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25:102–112. doi:10.18553/jmcp.2019.25.1.102
  • Pani L. Farmaci Biotecnologici e Biosimilari: innovazione e sostenibilità del sistema pubblico, AIFA[Biotechnological and biosimilar drugs: innovation and sustainability of the public system, Italian Medicines Agency]. Available from: https://www.senato.it/documenti/repository/commissioni/comm12/documenti_acquisiti/Prof.%20PANI%20aifa.pdf. Accessed April 5, 2023.
  • Agenzia Italiana del Farmaco. Secondo Position Paper AIFA sui Farmaci Biosimilari [Second Position Paper on Biosimilar Medicines - Italian Medicines Agency]. Available from: https://www.aifa.gov.it/-/secondo-position-paper-aifa-sui-farmaci-biosimilari. Accessed April 10, 2018.
  • Holloway K, van Dijk L. The world medicines situation 2011. Rational use of medicines. Geneva: World Health Organization; 2011. Available from: http://narst.dmsc.moph.go.th/manuals/The%20World%20Medicines%20Situation%202011%20-%20Rational%20Use%20of%20Medicines.pdf. Accessed April 5, 2018
  • European Medicines Agency and European Commission. Agenzia Europea dei Medicinali e Commissione Europea. Medicinali biosimilari nell’UE - Guida informativa per gli operatori sanitari.[Biosimilar medicines in the EU - Information guide for healthcare professionals]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_it.pdf. Accessed October 2, 2019.
  • National Observatory on the use of Medicines. L’uso dei farmaci in Italia. Rapporto Nazionale 2021. Roma: Agenzia Italiana del Farmaco.[The use of drugs in Italy. National Report 2021. Rome: Italian Medicines Agency]. Roma: Agenzia Italiana del Farmaco. Available from: https://www.aifa.gov.it/-/presentato-il-rapporto-nazionale-2021-l-uso-dei-farmaci-in-italia-. Accessed July 29, 2022.
  • Linares A, Fernandez C, Asensi D, et al. Budgetary impact of biosimilar prescription in the treatment of rheumatic diseases. Eur J Hosp Pharm. 2020;27(Suppl 1):A133–A134.
  • Stoffer MA, Smolen JS, Woolf A, et al. Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis. 2014;73:902–905. doi:10.1136/annrheumdis-2013-203743
  • Pasina L, Casadei G, Nobili A. A survey among hospital specialists and pharmacists about biosimilars. Eur J Intern Med. 2016;35:e31–e33. doi:10.1016/j.ejim.2016.07.010
  • Carrara G, Scirè CA, Zambon A, et al. A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case–control and cohort diagnostic accuracy studies. Results from the RECord linkage on rheumatic diseases study of the Italian society for rheumatology. BMJ Open. 2015;5(1):e006029. doi:10.1136/bmjopen-2014-006029
  • Kay J, Schoels MM, Dörner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165–174. doi:10.1136/annrheumdis-2017-211937
  • Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. are differences related to country’s wealth? Ann Rheum Dis. 2014;73:2010–2021. doi:10.1136/annrheumdis-2013-203819
  • Van der Heijde D, Aletaha D, Carmona L, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74:8–13. doi:10.1136/annrheumdis-2014-206350
  • Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.